Dr Debora Barton has over 20 years of experience in the field of oncology.
After practicing oncology as a physician and clinical trial investigator, she spent five years at Novartis and five years at Celgene in medical affairs and clinical development roles.
Dr Barton also has extensive experience working with cell therapy products. She was the senior vice president of clinical and head of safety at the clinical-stage company Iovance, who are developing T cell therapies for cancer treatment.
Dr Barton has been the chief medical officer of Carisma Therapeutics, a clinical-stage biopharmaceutical company developing innovative immunotherapies including the first-in-class chimeric antigen receptor (CAR) macrophages for the treatment of certain cancers.
Dr Barton is a member of the Manhattan Board of Directors for the American Cancer Society and the Medical Advisory Board of the Tigerlily Foundation, a national breast cancer foundation providing education, awareness, advocacy and hands-on support to young women before, during and after breast cancer.
